Old Web
English
Sign In
Acemap
>
authorDetail
>
Kirk Wilenius
Kirk Wilenius
Medicine
Pathology
Prostate cancer
Progressive disease
Toxicity
5
Papers
16
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (5)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
A germline microRNA-based biomarker signature of immune-associated toxicity to anti-PD1/PDL1 therapy.
2019
Journal of Clinical Oncology
Joanne B. Weidhaas
Aaron Scheffler
David W. Salzman
Anusha Kalbasi
Kirk Wilenius
Emily Rietdorf
Mara Heilig
Mattias Pitka
Caroline Desler
Dan Ruan
Antoni Ribas
Alexandra Drakaki
Mark C. Scholz
Donatello Telesca
Show All
Source
Cite
Save
Citations (0)
Real-World Experience with Pembrolizumab in Recurrent or Advanced Prostate Cancer
2019
Clinical Genitourinary Cancer
Julianna Higa
Kirk Wilenius
Shannon Savino
Claire Larsen
Mark C. Scholz
Nicholas J. Vogelzang
Show All
Source
Cite
Save
Citations (3)
Survival after sipuleucel-T (SIP-T) and low-dose ipilimumab (IPI) in men with metastatic, progressive, castrate-resistant prostate cancer (M-CRPC).
2018
Journal of Clinical Oncology
Justine Ku
Kirk Wilenius
Claire Larsen
Kyle De Guzman
Steven Yoshinaga
Jeffrey S. Turner
Richard Y. Lam
Mark C. Scholz
Show All
Source
Cite
Save
Citations (8)
Pembrolizumab for recurrent or advanced prostate cancer.
2018
Journal of Clinical Oncology
Juliana Higa
Kirk Wilenius
Joanne B. Weidhaas
Claire Larsen
Richard Y. Lam
Jeffrey S. Turner
Mark C. Scholz
Show All
Source
Cite
Save
Citations (5)
A microRNA-based signature predicting immune-related toxicity (iRAEs) to pembrolizumab in prostate cancer patients.
2018
Journal of Clinical Oncology
Joanne B. Weidhaas
Kirk Wilenius
Aaron Scheffler
Juliana Higa
Donatello Telesca
Mark C. Scholz
Show All
Source
Cite
Save
Citations (0)
1
map